Phase III clinical trial - Hématologie Lymphome non Hodgkinien
M20-621
Hématologie Lymphome non Hodgkinien
Ouvert depuis le: 04.27.2024
Site: Saint-Cloud
Public cible
Adulte
A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in;Combination with R-CHOP Compared to R-CHOP in Subjects with New Diagnosed Diffuse Large B-Cell;Lymphoma (DLBCL).
Description de l'essai
The primary objective of this study is to determine whether adding epcoritamab to 6 cycles of standard R-CHOP protocol followed by 2 cycles of epcoritamab can prolong progression-free survival (PFS) compared to 6 cycles of R- Standard CHOP alone followed by 2 cycles of rituximab in patients with newly identified DLBCL having an IPI of 2-5
Liens utiles